Bleomycin induced lung fibrosis increases work of breathing in the mouse
Introduction
In fibrotic lungs, the pressure-volume (PV) curve and hence the mechanical properties of the lung change in a manner that implies alteration in collagen elasticity. Collagen is an important load-bearing element within the lung. Total collagen content in the fibrotic lung increases and is accompanied by a decrease in lung function [1]. The relationship between the molecular organization of collagen fibers and the in vivo PV curve is not fully understood. In the bleomycin induced mouse model of pulmonary fibrosis, the small size of the mouse and the variable distribution of fibrotic foci in the lungs present significant challenges for the assessment of lung function. Histological analysis is a robust qualitative method for assessing lung fibrosis in this model; however, measuring lung function provides a quantitative assessment that may have an advantage in detecting improvement in lung stiffness (fibrosis) before it may become overtly evident histologically. Our aim was to determine a sensitive method for assessing lung function in bleomycin treated mice that correlated with the degree of lung fibrosis as measured by collagen immunohistochemistry.
Lung function data were calculated in three ways (the single compartment model, constant phase model, and work of breathing) using a flexiVent computer controlled ventilator. Dynamic PV curves measured by inflating and deflating the lungs (lung PV loops) can be used to calculate the work performed in ventilating the lung, since the product of pressure and volume is a unit of work. This study demonstrated that of the lung function parameters measured in the bleomycin induced mouse model of pulmonary fibrosis, the volume normalized work of breathing measured at 30 ml/kg was the most significantly increased and correlate most strongly with the lung fibrosis histopathology score.
Section snippets
Animals
Male C57BL/6 mice weighing 22–24 g on day 0 (7–9 weeks old, Jackson Laboratories, n = 7–8 animals per group) were used in this study. Animal care and experimental procedures used in this study were approved by the Roche Animal Care and Use Committee (RACUC, Nutley, NJ, USA) which is a facility accredited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC).
Bleomycin induced mouse model of pulmonary fibrosis
Bleomycin sulphate (MP Biomedicals, Solon, OH, USA) was dissolved in 0.9% saline at a concentration of
Effects on body weight
A significant decrease in body weight after 2 U/kg, i.t. bleomycin administration was initially observed (Fig. 1). The decrease in body weight in the bleomycin treated group stabilized after day 7 and daily increases in body weight resumed in the bleomycin treated group after day 9. The average body weight of the bleomycin treated group (25.1 ± 0.6 g) remained significantly lower that the saline control group (26.8 ± 0.4 g) on day 21. None of the 2 U/kg bleomycin treated animals died before day
Discussion
This study demonstrated that among the lung function parameters we have measured in the bleomycin induced mouse model of pulmonary fibrosis, the volume normalized work of breathing measured at 30 ml/kg was the most significantly increased and best correlate of the lung fibrosis histopathology score. Histological analysis is a robust but qualitative method to assess lung fibrosis. While lung function is not as robust of an indicator of pulmonary fibrosis, improvements in lung function can be
Conflicts of interest
All authors are full-time employees of the Hoffmann – La Roche Inc.
Acknowledgements
The authors would like to thank Dr. Martin Kolb (McMaster University) for his stimulating discussion on the applicability of this work. We would also like to thank Lorena Renteria, Jacob LaStant, and John Woods for their assistance with the preparation and harvest of the lung tissues.
References (20)
- et al.
Non-invasive pulmonary aerosol delivery in mice by the endotracheal route
Eur J Pharm Biopharm
(2005) - et al.
The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?
Int J Biochem Cell Biol
(2008) - et al.
Alteration of bronchoalveolar lavage cell populations following bleomycin treatment in mice
Toxicol Appl Pharmacol
(1989) - et al.
Murine strain differences in pulmonary bleomycin metabolism
Biochem Pharmacol
(1991) - et al.
Studies on respiratory mechanics and the work of breathing in pulmonary fibrosis
Am J Med
(1959) - et al.
Biomechanics of the lung parenchyma: critical roles of collagen and mechanical forces
J Appl Physiol
(2005) Lung mechanics
(2009)- et al.
Manual and automated leukocyte differentiation in bronchoalveolar lavage fluids from rodent models of pulmonary inflammation
Comp Clin Pathol
(2009) - et al.
Rapid tracheal infusion method for routine lung fixation using rat and guinea pig
Toxicol Pathol
(1981) - et al.
Simple method of estimating severity of pulmonary fibrosis on a numerical scale
J Clin Pathol
(1988)
Cited by (32)
A novel BRD4 degrader, ARV-825, attenuates lung fibrosis through senolysis and antifibrotic effect
2023, Respiratory InvestigationInhalation treatment of idiopathic pulmonary fibrosis with curcumin large porous microparticles
2018, International Journal of PharmaceuticsFTY720 promotes pulmonary fibrosis when administered during the remodelling phase following a bleomycin-induced lung injury
2017, Pulmonary Pharmacology and TherapeuticsTherapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model
2016, Pulmonary Pharmacology and Therapeutics